Biolase (BIOL) Trading Up 7.7% on Insider Buying Activity

Biolase, Inc. (NASDAQ:BIOL) shares were up 7.7% during mid-day trading on Wednesday after an insider bought additional shares in the company. The stock traded as high as $0.43 and last traded at $0.42. Approximately 1,446,100 shares were traded during mid-day trading, an increase of 821% from the average daily volume of 157,019 shares. The stock had previously closed at $0.39.

Specifically, major shareholder Larry N. Feinberg bought 12,545,615 shares of Biolase stock in a transaction that occurred on Tuesday, December 5th. The stock was acquired at an average price of $0.43 per share, for a total transaction of $5,394,614.45. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 7.10% of the stock is currently owned by company insiders.

Separately, ValuEngine upgraded shares of Biolase from a “sell” rating to a “hold” rating in a research note on Monday, October 2nd.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at

Biolase Company Profile

BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.

Receive News & Ratings for Biolase Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolase Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply